(PubMed) Juraschek SP, Gaziano JM, Glynn RJ, et al
BREAKING NEWS APRIL 15, 2026 - In a welcome announcement to the SSRP community, the FDA reported today that it will imminently remove the following bulk drug substances from category 2: BPC-157, LL-37, DiHexa, DSIP, Epitalon, *GHK-Cu (injectable only), KPV, PEG-MGF, Melanotan II, MOTs-C, Semax, and TB-500
This is a small waste relative to the risk of using degraded peptide
The reconstituted solution should be refrigerated at 28C and used within the recommended timeframe, with aliquoting advised to prevent peptide degradation from repeated freeze-thaw cycles.
With anti-inflammatory benefits the Master Antioxidant works effectively at the cellular level to support general health
At EVEXIAS Medical Centers, we believe aesthetic excellence is the outward expression of internal health